GRI Bio (GRI) announced positive flow cytometry data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis, IPF. Immune cell samples from lung bronchoalveolar lavage, BAL, fluid and peripheral blood mononuclear cells, PBMC, demonstrated iNKT inhibition and a clear immunomodulatory shift towards an anti-fibrotic profile, producing more anti-fibrotic interferon-gamma and less pro-fibrotic interleukin-4, IL-13, IL-17A, IL-22, and transforming growth factor-beta. “Our Phase 2a study was intentionally designed to assess a broad range of clinical, biomarker, and mechanistic endpoints,” Dr. Hertz continued. “The immune cell data announced today are highly consistent with our earlier findings on collagen turnover, lung tissue repair, and improvements in pulmonary function, further strengthening the overall clinical proof-of-concept for GRI-0621.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- Promising Potential of GRI-0621 in IPF Treatment: A Buy Recommendation by Matthew Keller
- GRI Bio Closes $8 Million Public Offering
- GRI Bio Launches $6.7 Million Public Offering
- GRI Bio prices 10.67M shares at 75c in public offering
- GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints